NU-MELOXICAM 7.5 MG
MELOXICAM : 7.5 MG · DIN 02335506 · NU-PHARM INC
Health Canada status: CANCELLED (UNRETURNED ANNUAL)
What is NU-MELOXICAM?
NU-MELOXICAM 7.5 MG contains MELOXICAM : 7.5 MG. It is listed in the Health Canada Drug Product Database under DIN 02335506, held by NU-PHARM INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled (unreturned annual), status dated 28-Mar-2018. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is NU-MELOXICAM used for?
Symptomatic treatment of adult rheumatoid arthritis and painful osteoarthritis (arthrosis, degenerative joint disease).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02335506 |
|---|---|
| Brand name | NU-MELOXICAM |
| Generic / active ingredient | MELOXICAM : 7.5 MG |
| Manufacturer | NU-PHARM INC |
| Strength | 7.5 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | M01AC06 MELOXICAM |
| AHFS class | 28:08.04.92 |
| Biosimilar | No |
| Health Canada status | CANCELLED (UNRETURNED ANNUAL) |
| Status date | 28-Mar-2018 |
How is it administered?
Rheumatoid arthritis: 15 mg once daily (may reduce to 7.5 mg). Osteoarthritis: 7.5 mg once daily (may increase to 15 mg). Use lowest effective dose for shortest duration. Max 15 mg/day.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store at 15-30°C (implied by standard monograph sections, though specific text for section 15 is missing from snippet).
How is it supplied?
Not explicitly detailed in provided text (referenced in section 16, but text cuts off). Summary table lists 7.5 & 15 mg strengths.
Contraindications
Post-CABG surgery; pregnancy/breastfeeding; hypersensitivity to meloxicam/ASA/NSAIDs; active ulcer/GI bleeding; liver impairment; severe renal impairment (CrCl <30 mL/min); severe heart failure.
Warnings and precautions
Risk of serious cardiovascular (thrombotic events, MI, stroke) and gastrointestinal (ulcer, perforation, bleed) events. May cause hypertension, fluid retention, and renal toxicity.
What can be used instead?
Other Canadian products sharing ATC code M01AC06 MELOXICAM. 10 of 30 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-MELOXICAM | 15 MG | TABLET | APOTEX INC | MARKETED | DIN 02248974 |
| APO-MELOXICAM | 7.5 MG | TABLET | APOTEX INC | MARKETED | DIN 02248973 |
| AURO-MELOXICAM | 15 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02390892 |
| AURO-MELOXICAM | 7.5 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02390884 |
| MELOXICAM | 15 MG | TABLET | SANIS HEALTH INC | MARKETED | DIN 02353156 |
| MELOXICAM | 7.5 MG | TABLET | SANIS HEALTH INC | MARKETED | DIN 02353148 |
| PMS-MELOXICAM | 15 MG | TABLET | PHARMASCIENCE INC | MARKETED | DIN 02248268 |
| PMS-MELOXICAM | 7.5 MG | TABLET | PHARMASCIENCE INC | MARKETED | DIN 02248267 |
| TEVA-MELOXICAM | 15 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 02258323 |
| TEVA-MELOXICAM | 7.5 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 02258315 |
Who else supplies MELOXICAM worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. MELOXICAM appears in 1805 registered pack listings across 14 markets, published on 11 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.